Circulating antibodies (AB) to the nicotinic acetyloholine receptor (AChR) at the neuromuscular junction are probably the main cause of the transmission defect in myasthenia gravis (MG) (for review see Lennon (EPP) (2) a decrease in the number of AChR measured by a-bungarotoxin (a-Butx) binding and (3) a decremental response and clinical weakness in some animals.4-6 Accelerated degradation of membrane bound AChR has been observed in mice treated identically. 7 There is evidence from studies using muscle cell cultures that native IgG antibodies or bivalent (F(ab')2 fragments are needed to induce accelerated degradation of AChR but Fab fragments are inactive., In this study we investigated the effects of Fab fragments and those of IgG from myasthenic sera on neuromuscular junctions in vivo using the mouse transfer model. It will be demonstrated that Fab fragments (1) bind to AChR but do not reproduce the myasthenic transmission defect, and (2) completely inhibit the effect of IgG on MEPP amplitudes when transferred simultaneously.
Material and methods
Patients Serum was obtained from three patients with myasthenia gravis (MG) Fab (fig 4) by incubation with rabbit anti-Fab antibody followed by 
